HK1107651A1 - Inhibitors of the interaction between mdm2 and p53 mdm2 - Google Patents
Inhibitors of the interaction between mdm2 and p53 mdm2Info
- Publication number
- HK1107651A1 HK1107651A1 HK07113244.0A HK07113244A HK1107651A1 HK 1107651 A1 HK1107651 A1 HK 1107651A1 HK 07113244 A HK07113244 A HK 07113244A HK 1107651 A1 HK1107651 A1 HK 1107651A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- mdm2
- inhibitors
- interaction
- Prior art date
Links
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 title 2
- 101150024228 mdm2 gene Proteins 0.000 title 2
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003993 interaction Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04077630 | 2004-09-22 | ||
US61390204P | 2004-09-28 | 2004-09-28 | |
PCT/EP2005/054604 WO2006032631A1 (en) | 2004-09-22 | 2005-09-16 | Inhibitors of the interaction between mdm2 and p53 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1107651A1 true HK1107651A1 (en) | 2008-04-11 |
Family
ID=34928531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07113244.0A HK1107651A1 (en) | 2004-09-22 | 2007-12-04 | Inhibitors of the interaction between mdm2 and p53 mdm2 |
Country Status (30)
Country | Link |
---|---|
US (2) | US7834016B2 (ja) |
EP (1) | EP1809622B1 (ja) |
JP (1) | JP5156378B2 (ja) |
KR (1) | KR101331786B1 (ja) |
CN (1) | CN101023074B (ja) |
AP (1) | AP2446A (ja) |
AR (1) | AR053412A1 (ja) |
AT (1) | ATE474833T1 (ja) |
AU (1) | AU2005286525B2 (ja) |
BR (1) | BRPI0515594B8 (ja) |
CA (1) | CA2579915C (ja) |
CR (1) | CR9081A (ja) |
DE (1) | DE602005022472D1 (ja) |
DK (1) | DK1809622T3 (ja) |
EA (1) | EA012452B1 (ja) |
EC (1) | ECSP077335A (ja) |
ES (1) | ES2349358T3 (ja) |
HK (1) | HK1107651A1 (ja) |
HR (1) | HRP20100561T1 (ja) |
IL (1) | IL182009A (ja) |
MX (1) | MX2007003375A (ja) |
MY (1) | MY136800A (ja) |
NO (1) | NO341281B1 (ja) |
NZ (1) | NZ553646A (ja) |
SG (1) | SG155941A1 (ja) |
SI (1) | SI1809622T1 (ja) |
TW (1) | TWI372758B (ja) |
UA (1) | UA91027C2 (ja) |
WO (1) | WO2006032631A1 (ja) |
ZA (1) | ZA200702341B (ja) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GEP20115364B (en) | 2005-05-10 | 2011-12-26 | Intermune Inc | Method for modulation of stress-activated protein kinase system |
CN101228161B (zh) * | 2005-05-20 | 2012-10-10 | 沃泰克斯药物股份有限公司 | 适用作蛋白激酶抑制剂的吡咯并吡啶类 |
WO2007107543A1 (en) | 2006-03-22 | 2007-09-27 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between mdm2 and p53 |
DE602007007065D1 (de) * | 2006-03-22 | 2010-07-22 | Janssen Pharmaceutica Nv | Cycloalkylaminderivate als inhibitoren der wechselwirkung zwischen mdm2 und p53 |
PL2010493T3 (pl) * | 2006-04-12 | 2016-08-31 | Merck Sharp & Dohme | Pirydyloamidy jako antagoniści kanałów wapniowych typu t |
US8138205B2 (en) | 2006-07-07 | 2012-03-20 | Kalypsys, Inc. | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 |
MX2009000148A (es) | 2006-07-07 | 2009-10-26 | Kalypsys Inc | Inhibidores heteroaril biciclicos de fosfodiesterasa 4. |
US7622495B2 (en) | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
WO2008121442A2 (en) * | 2007-02-09 | 2008-10-09 | The Uab Research Foundation | Pa28-gamma regulation in cells |
US20100129933A1 (en) * | 2007-04-26 | 2010-05-27 | Forschungszentrum Karlsruhe Gmbh | Method for detecting the binding between mdm2 and the proteasome |
WO2009019274A1 (en) * | 2007-08-06 | 2009-02-12 | Janssen Pharmaceutica Nv | Substituted phenylenediamines as inhibitors of the interaction between mdm2 and p53 |
US8288377B2 (en) | 2007-09-21 | 2012-10-16 | Janssen Pharmaceutica N.V. | Inhibitors of the interaction between MDM2 and p53 |
JO2704B1 (en) * | 2007-09-21 | 2013-03-03 | جانسين فارماسوتيكا ان في | Interference inhibition factors between MD2 and B53 |
WO2009054984A1 (en) * | 2007-10-24 | 2009-04-30 | Merck & Co., Inc. | Heterocycle phenyl amide t-type calcium channel antagonists |
US8268777B2 (en) * | 2007-12-05 | 2012-09-18 | Enanta Pharmaceuticals, Inc. | Oximyl macrocyclic derivatives |
US8193346B2 (en) * | 2007-12-06 | 2012-06-05 | Enanta Pharmaceuticals, Inc. | Process for making macrocyclic oximyl hepatitis C protease inhibitors |
ES2567283T3 (es) | 2008-06-03 | 2016-04-21 | Intermune, Inc. | Compuestos y métodos para tratar trastornos inflamatorios y fibróticos |
JP5612611B2 (ja) | 2009-02-04 | 2014-10-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap | 抗癌剤としてのインドール誘導体 |
WO2010107485A1 (en) * | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
EP2311823A1 (en) | 2009-10-15 | 2011-04-20 | AC Immune S.A. | 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases |
AU2010319595B2 (en) | 2009-11-12 | 2015-09-17 | The Regents Of The University Of Michigan | Spiro-oxindole MDM2 antagonists |
BR112012016376A2 (pt) | 2009-12-30 | 2019-09-24 | Arqule Inc | compostos de pirrolo-aminopirimida substituída |
US20130102631A1 (en) * | 2010-07-02 | 2013-04-25 | Syngenta Crop Protection Llc | Novel microbiocidal dioxime ether derivatives |
FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
EP2638046A4 (en) | 2010-11-12 | 2014-06-25 | Univ Michigan | SPIRO-OXINDOLES ANTAGONISTS OF MDM2 |
WO2012155066A2 (en) | 2011-05-11 | 2012-11-15 | Shaomeng Wang | Spiro-oxindole mdm2 antagonists |
US8815926B2 (en) * | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
RU2509808C1 (ru) * | 2012-10-30 | 2014-03-20 | Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) | СПОСОБ ОПРЕДЕЛЕНИЯ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК НЕМЕЛКОКЛЕТОЧНОГО РАКА ЛЕГКИХ К ДЕЙСТВИЮ ПРЕПАРАТОВ, РЕАКТИВИРУЮЩИХ БЕЛОК р53 |
KR20140059002A (ko) * | 2012-11-07 | 2014-05-15 | 한국과학기술원 | 다제내성 종양 치료를 위한 항암제 및 치료방법 |
CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
DK3102576T3 (da) | 2014-02-03 | 2019-07-22 | Vitae Pharmaceuticals Llc | Dihydropyrrolopyridininhibitorer af ror-gamma |
MX2016012808A (es) | 2014-04-02 | 2017-01-05 | Intermune Inc | Piridinonas anti-fibroticas. |
PL3207043T6 (pl) | 2014-10-14 | 2020-11-02 | Vitae Pharmaceuticals, Llc | Inhibitory dihydropirolopirydynowe ror-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
KR102595395B1 (ko) | 2015-02-20 | 2023-10-27 | 다이이찌 산쿄 가부시키가이샤 | 암의 병용 치료법 |
UA124228C2 (uk) * | 2015-05-11 | 2021-08-11 | Басф Се | Спосіб одержання 4-амінопіридазинів |
EP3872073A1 (en) | 2015-05-11 | 2021-09-01 | Basf Se | Process for preparing 4-amino-pyridazines |
DK3331876T3 (da) | 2015-08-05 | 2021-01-11 | Vitae Pharmaceuticals Llc | Modulators of ror-gamma |
BR112018002399A2 (pt) | 2015-08-06 | 2018-09-25 | Chimerix, Inc. | nucleosídeos de pirrolopirimidina e análogos dos mesmos, úteis como agentes antivirais |
MA53943A (fr) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals Llc | Modulateurs de ror-gamma |
US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
JP7037500B2 (ja) | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Mdm2タンパク質分解剤 |
EP3440082A1 (en) | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
SG11201901197PA (en) | 2016-08-24 | 2019-03-28 | Arqule Inc | Amino-pyrrolopyrimidinone compounds and methods of use thereof |
AU2018307919B2 (en) | 2017-07-24 | 2022-12-01 | Vitae Pharmaceuticals, Llc | Inhibitors of RORϒ |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
WO2019060692A1 (en) | 2017-09-21 | 2019-03-28 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES |
CN108409839B (zh) * | 2018-02-13 | 2020-08-11 | 中国人民解放军军事科学院军事医学研究院 | 一种MDM2与p53相互作用的多肽抑制剂及其应用 |
WO2019164794A1 (en) | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Methods of use for trisubstituted benzotriazole derivatives |
WO2021155467A1 (en) | 2020-02-04 | 2021-08-12 | Mindset Pharma Inc. | 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
TR202002325A2 (tr) * | 2020-02-17 | 2021-08-23 | Bahcesehir Ueniversitesi | Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-4 |
CN113293046B (zh) * | 2021-05-26 | 2021-11-30 | 安徽博洋润滑科技有限公司 | 一种低发尘润滑脂及其制备方法 |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9201755D0 (en) | 1992-01-28 | 1992-03-11 | British Bio Technology | Compounds |
AUPO863197A0 (en) | 1997-08-18 | 1997-09-11 | Fujisawa Pharmaceutical Co., Ltd. | Novel derivatives |
US6861448B2 (en) | 1998-01-14 | 2005-03-01 | Virtual Drug Development, Inc. | NAD synthetase inhibitors and uses thereof |
US6309492B1 (en) | 1998-09-16 | 2001-10-30 | Marc A. Seidner | Polymer fill coating for laminate or composite wood products and method of making same |
UA71587C2 (uk) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Аміди антранілової кислоти та їхнє застосування як лікарських засобів |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
MXPA01009674A (es) * | 1999-03-24 | 2003-07-21 | Anormed Inc | Compuestos heterociclicos que se unen a receptores de quimiocina. |
AU1734401A (en) * | 1999-12-09 | 2001-06-18 | Mitsubishi Pharma Corporation | Carboxyamido derivatives |
AU9355101A (en) | 2000-09-15 | 2002-03-26 | Anormed Inc | Chemokine receptor binding heterocyclic compounds |
JP2004532209A (ja) | 2001-03-29 | 2004-10-21 | イーライ・リリー・アンド・カンパニー | 5−ht6受容体の拮抗薬としてのn−(2−アリールエチル)ベンジルアミン |
AU2002357728A1 (en) * | 2001-11-09 | 2003-05-19 | The Regents Of The University Of California | Alpha-helix mimicry by a class of organic molecules |
DE60227185D1 (de) | 2001-11-13 | 2008-07-31 | Ortho Mcneil Pharm Inc | Substituierte 1,4-benzodiazepine und ihre anwendung in der krebsbehandlung |
ES2301717T3 (es) | 2001-12-18 | 2008-07-01 | F. Hoffmann-La Roche Ag | Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores. |
GB0215650D0 (en) | 2002-07-05 | 2002-08-14 | Cyclacel Ltd | Bisarylsufonamide compounds |
GB0428187D0 (en) | 2004-12-23 | 2005-01-26 | Univ Liverpool | Cancer treatment |
US7947694B2 (en) * | 2005-01-14 | 2011-05-24 | Janssen Pharmaceutica Nv | Substituted pyrazolo[3,4-D]pyrimidines as cell cycle kinase inhibitors |
EP2314297A1 (en) | 2006-04-05 | 2011-04-27 | Novartis AG | Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer |
-
2005
- 2005-09-16 DK DK05786991.9T patent/DK1809622T3/da active
- 2005-09-16 SG SG200906267-0A patent/SG155941A1/en unknown
- 2005-09-16 WO PCT/EP2005/054604 patent/WO2006032631A1/en active Application Filing
- 2005-09-16 KR KR1020077008663A patent/KR101331786B1/ko active IP Right Grant
- 2005-09-16 AU AU2005286525A patent/AU2005286525B2/en not_active Ceased
- 2005-09-16 AT AT05786991T patent/ATE474833T1/de not_active IP Right Cessation
- 2005-09-16 EA EA200700699A patent/EA012452B1/ru not_active IP Right Cessation
- 2005-09-16 NZ NZ553646A patent/NZ553646A/en not_active IP Right Cessation
- 2005-09-16 CA CA2579915A patent/CA2579915C/en not_active Expired - Fee Related
- 2005-09-16 CN CN2005800317557A patent/CN101023074B/zh not_active Expired - Fee Related
- 2005-09-16 UA UAA200702657A patent/UA91027C2/ru unknown
- 2005-09-16 ES ES05786991T patent/ES2349358T3/es active Active
- 2005-09-16 DE DE602005022472T patent/DE602005022472D1/de active Active
- 2005-09-16 US US11/575,552 patent/US7834016B2/en not_active Expired - Fee Related
- 2005-09-16 AP AP2007003947A patent/AP2446A/xx active
- 2005-09-16 BR BRPI0515594A patent/BRPI0515594B8/pt not_active IP Right Cessation
- 2005-09-16 SI SI200531127T patent/SI1809622T1/sl unknown
- 2005-09-16 JP JP2007532886A patent/JP5156378B2/ja not_active Expired - Fee Related
- 2005-09-16 MX MX2007003375A patent/MX2007003375A/es active IP Right Grant
- 2005-09-16 EP EP05786991A patent/EP1809622B1/en active Active
- 2005-09-21 AR ARP050103960A patent/AR053412A1/es not_active Application Discontinuation
- 2005-09-21 TW TW094132574A patent/TWI372758B/zh not_active IP Right Cessation
- 2005-09-22 MY MYPI20054466A patent/MY136800A/en unknown
-
2007
- 2007-03-19 IL IL182009A patent/IL182009A/en active IP Right Grant
- 2007-03-20 ZA ZA200702341A patent/ZA200702341B/xx unknown
- 2007-03-22 EC EC2007007335A patent/ECSP077335A/es unknown
- 2007-04-20 CR CR9081A patent/CR9081A/es not_active Application Discontinuation
- 2007-04-23 NO NO20072058A patent/NO341281B1/no not_active IP Right Cessation
- 2007-12-04 HK HK07113244.0A patent/HK1107651A1/xx not_active IP Right Cessation
-
2010
- 2010-10-14 HR HR20100561T patent/HRP20100561T1/hr unknown
- 2010-11-03 US US12/938,633 patent/US8404683B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI372758B (en) | Inhibitors of the interaction between mdm2 and p53 | |
PL382308A1 (pl) | Związki heterocykliczne i sposoby stosowania | |
EP1787998A4 (en) | ANTIBODIES AND USE RELATING THERETO | |
IL191554A0 (en) | Lactam compounds and methods of using the same | |
EP1740532A4 (en) | CFTR INHIBITOR COMPOUNDS CONTAINING HYDRAZIDS AND USES THEREOF | |
EP1845563A4 (en) | PRECURSOR FILM AND METHOD FOR MANUFACTURING THE SAME | |
EP1742627A4 (en) | PDE4B HEMMER AND ITS USE | |
HK1087699A1 (en) | Gyrase inhibitors and uses thereof | |
IL172471A0 (en) | Gsk-3 inhibitors and uses thereof | |
IL185199A0 (en) | Indole compound and use thereof | |
IL190293A0 (en) | Nitrogen-containing heterocyclic compound and pharmaceutical application thereof | |
SI2203440T1 (sl) | Inhibitorji interakcije med MDM2 in P53 | |
GB0508895D0 (en) | Sealing devices and sealing methods | |
ZA200702380B (en) | Substituted heterocyclic compounds and uses thereof | |
IL177709A0 (en) | Caspase inhibitors and uses thereof | |
EP1753468A4 (en) | CARBORANYLPORPHYRINS AND USES THEREOF | |
GB0326520D0 (en) | Molluscicidal and anti-barnacle compounds | |
GB2418439B (en) | Rock-bit and rock-bit seal | |
IL181819A0 (en) | Enzyme inhibitors and uses thereof | |
IL183838A0 (en) | Thiazolium compounds and uses thereof | |
GB0402007D0 (en) | Acoustic devices and fluid-gauging | |
ZA200804872B (en) | Lactam compounds and methods of using the same | |
AU2006259113A8 (en) | Use of PDE1C and inhibitors thereof | |
GB0411257D0 (en) | Cassette and its use | |
TH124200B (th) | สารยับยั้งอันตรกิริยาระหว่าง mdm2 และ p53 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20170916 |